Voloridge Investment Management
SRPT icon

Voloridge Investment Management’s Sarepta Therapeutics SRPT Stock Holding History

Voloridge Investment Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.72M Sell
262,565
-169,970
-39% -$3.21M 0.02% 542
2026
Q1 		$9.41M Sell
432,535
-445,858
-51% -$8.63M 0.04% 523
2025
Q4 		$18.9M Sell
878,393
-430,345
-33% -$9.07M 0.07% 380
2025
Q3 		$25.2M Sell
1,308,738
-165,417
-11% -$2.95M 0.08% 288
2025
Q2 		$25.2M Buy
1,474,155
+1,016,827
+222% +$43.4M 0.09% 274
2025
Q1 		$29.2M Buy
+457,328
New +$48.1M 0.11% 258
2024
Q4 		– Sell
-38,973
Closed -$4.87M – 1368
2024
Q3 		$4.87M Sell
38,973
-249,644
-86% -$34.5M 0.02% 783
2024
Q2 		$45.6M Sell
288,617
-141,852
-33% -$18.2M 0.17% 182
2024
Q1 		$55.7M Buy
430,469
+71,921
+20% +$8.81M 0.2% 136
2023
Q4 		$34.6M Buy
358,548
+260,569
+266% +$25M 0.14% 196
2023
Q3 		$11.9M Buy
97,979
+2
+0% +$226 0.06% 415
2023
Q2 		$11.2M Sell
97,977
-196,233
-67% -$25.3M 0.05% 433
2023
Q1 		$40.6M Buy
294,210
+133,341
+83% +$17.3M 0.2% 148
2022
Q4 		$20.8M Buy
160,869
+95,066
+144% +$11M 0.12% 253
2022
Q3 		$7.27M Buy
65,803
+46,813
+247% +$4.72M 0.04% 536
2022
Q2 		$1.42M Sell
18,990
-116,161
-86% -$8.55M 0.01% 1106
2022
Q1 		$10.6M Sell
135,151
-10,171
-7% -$779K 0.06% 396
2021
Q4 		$13.1M Sell
145,322
-35,745
-20% -$3.06M 0.07% 391
2021
Q3 		$16.7M Sell
181,067
-153,404
-46% -$11.8M 0.11% 257
2021
Q2 		$26M Sell
334,471
-197,484
-37% -$15M 0.18% 135
2021
Q1 		$39.6M Buy
+531,955
New +$49.1M 0.29% 74
2020
Q3 		– Sell
-29,240
Closed -$4.69M – 1489
2020
Q2 		$4.69M Buy
+29,240
New +$3.98M 0.05% 369
2019
Q4 		– Sell
-115,270
Closed -$8.68M – 1339
2019
Q3 		$8.68M Buy
+115,270
New +$13.6M 0.15% 154
2019
Q1 		– Sell
-40,684
Closed -$4.44M – 1052
2018
Q4 		$4.44M Buy
+40,684
New +$5.09M 0.2% 121
2018
Q3 		– Sell
-137,118
Closed -$18.1M – 451
2018
Q2 		$18.1M Sell
137,118
-28,848
-17% -$2.72M 0.49% 48
2018
Q1 		$12.3M Buy
165,966
+10,562
+7% +$704K 0.29% 56
2017
Q4 		$8.65M Buy
+155,404
New +$8.23M 0.19% 132
2017
Q1 		– Sell
-159,580
Closed -$4.38M – 675
2016
Q4 		$4.38M Buy
159,580
+155,880
+4,213% +$6.26M 0.09% 276
2016
Q3 		$227K Buy
+3,700
New +$112K ﹤0.01% 209
2015
Q4 		– Sell
-37,997
Closed -$1.22M – 295
2015
Q3 		$1.22M Buy
+37,997
New +$1.29M 0.06% 210

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Voloridge Investment Management's SRPT Position: Q2 2026 in Review

Voloridge Investment Management reduced its Sarepta Therapeutics (SRPT) stake by 39% in Q2 2026, selling an estimated $3.21M and leaving 262,565 shares worth $4.72M. The position accounts for 0.02% of the portfolio, ranked #542.

Voloridge Investment Management first reported a position in SRPT in Q3 2015 and has held it in 30 quarters since. The position peaked at $55.7M in Q1 2024. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Voloridge Investment Management held 262,565 shares of Sarepta Therapeutics worth $4.72M as of Q2 2026.
  • Voloridge Investment Management sold 169,970 Sarepta Therapeutics shares in Q2 2026, an estimated $3.21M.
  • Sarepta Therapeutics made up 0.02% of Voloridge Investment Management's portfolio in Q2 2026, its #542 holding.
  • Voloridge Investment Management first reported a position in Sarepta Therapeutics in Q3 2015 and has held it in 30 quarters since.
  • Voloridge Investment Management's Sarepta Therapeutics position peaked at $55.7M in Q1 2024.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Voloridge Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.